Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies

Lancet

Volumn 360, Issue 9349, 2002, Pages 1903-1913

  Lewington, Sarah ^a   Clarke, Robert ^a   Qizilbash, Nawab ^a   Peto, Richard ^a   Collins, Rory ^a  

^a CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; REGRESSION ANALYSIS; SEX DIFFERENCE; STROKE; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE;

EID: 0037079309     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)11911-8     Document Type: Article

References (26)

1. Collaborative overview ("meta-analysis") of prospective observational studies of the associations of usual blood pressure and usual cholesterol levels with common causes of death: protocol for the second cycle of the Prospective Studies Collaboration. J Cardiovasc Risk. 6:1999;315-329.
2. MacMahon S., Peto R., Cutler J., et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 335:1990;765-774.
3. Rospective P. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Lancet. 346:1995;647-653.
4. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet. 352:1998;1801-1807.
5. Martin M.J., Browner W.S., Hulley S.B., Kuller L.H., Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361 662 men. Lancet. 2:1986;933-936.
6. Clarke R., Shipley M., Lewington S., et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol. 150:1999;341-354.
7. Cox D.R. Regression models and life tables. J R Stat Soc. 34:1972;187-220.
8. Easton D.F., Peto J., Babiker A.G. Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med. 10:1991;1025-1035.
9. Port S., Demer L., Jennrich R., Walter D., Garfinkel A. Systolic blood pressure and mortality. Lancet. 355:2000;175-180.
10. Collins R., Peto R., MacMahon S., et al. Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 335:1990;827-838.
11. Collins R., MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull. 50:1994;272-298.
12. Gueyffier F., Boutitie F., Boissel J.-P., et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men: a meta-analysis of individual patient data from randomised controlled trials. Ann Intern Med. 126:1997;761-767.
13. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 355:2000;1955-1964.
14. White W.B. The systolic blood pressure versus pulse pressure controversy. Am J Cardiology. 87:2001;1278-1281.
15. Franklin S.S., Larsen M.G., Khan S.A., et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 103:2001;1245-1249.
16. Gueyffier F., Boissel J.P., Boutitie F., et al. Effect of antihypertensive treatment in patients having already suffered from stroke: gathering the evidence. Stroke. 28:1997;2557-2562.
17. Staessen J.A., Gasowski J., Wang J.G., et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 355:2000;865-872.
18. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 358:2001;1033-1041.
19. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 342:2000;145-153.
20. Graudal N.A., Galloe A.M., Anders M., Garred P. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols and triglyceride: a meta-analysis. JAMA. 279:1998;1383-1391.
21. Sacks F.M., Svetkey L.P., Vollmer W.M., et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 344:2001;3-10.
22. Tuomilehto J., Jousilahti P., Rastenyte D., et al. Urinary sodium excretion and cardiovascular mortality in Finland: a prospective study. Lancet. 357:2001;848-851.
23. Murray CJ, Lopez AD. Global Pattern of Cause of Death and Burden of Disease in 1990, with Projections to 2020 - Investing in Health Research and Development: Report of the Ad Hoc Committee on Health Research Relating to Future Intervention Options. Geneva: WHO, 1996.
24. Chen J, Campbell TC, Li J, Peto R. Diet, Lifestyle and Mortality in China: A Study of the Characteristics of 65 Chinese Counties. Oxford: Oxford University Press, 1990 (updated at http://www.ctsu.ox.ac.uk ).
25. Thorvaldsen P., Asplund K., Kuulasmaa K., Rajakangas A.-M., Schroll M. Stroke incidence, case fatality, and mortality in the WHO MONICA Project. Stroke. 26:1995;361-367.
26. Kuulasmaa K., Tunstall-Pedoe H., Dobson A., et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet. 355:2000;675-687.